Sofetabart mipitecan is a novel folate receptor alpha (FR?) antibody-drug conjugate (ADC) leveraging proprietary linker technology and an exatecan payload to target tumor cells
The development marks an important step in Sigachi's strategic focus on expanding its presence in complex, high-value specialty APIs, aligned with global demand for advanced therapies in rare and chronic disease segments
The injectable borofalan (10B), developed by CNNC Headway—a subsidiary of China Isotope & Radiation Corporation (CIRC) under the China National Nuclear Corporation (CNNC)—has officially entered Phase I clinical trials
Waskyra is an ex vivo gene therapy that uses patients’ own CD34+ hematopoietic stem and progenitor cells, genetically engineered with a lentiviral vector
DNA nanorobots—tiny, self-assembling machines capable of detecting diseases in blood samples within 2–4 hours
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
Over 8.8?million Indians aged 60 and above currently live with dementia,
India in the Changing Landscape of Life-Sciences Research & Development
The capital was raised via multiple-tenure non-convertible debentures (NCDs) and commercial papers
The company recorded revenue of Rs. 1,065 crore in the third quarter of FY26
Subscribe To Our Newsletter & Stay Updated
